| Also known as |
L-OHP |
| Blood pressure |
No significant effect |
| Chemical name |
Oxaliplatin |
| Dosage (medical) |
Typically 85 mg/mВІ administered intravenously every 2 weeks |
| Dosage (sports) |
Not applicable |
| Effects |
Inhibits DNA synthesis by forming DNA adducts, leading to cell death and suppression of tumor growth |
| Formula |
C8H14N2O4Pt |
| Half-life |
Approximately 14 days (total platinum) |
| Hepatotoxicity |
Low |
| Lab Test |
Monitoring of complete blood count, liver enzymes, and kidney function |
| Main action |
Antineoplastic (chemotherapeutic agent) |
| Side effects |
Peripheral neuropathy, nausea, vomiting, diarrhea, neutropenia, ototoxicity |
| Storage conditions |
Store at 20В°C to 25В°C (68В°F to 77В°F) |
| Strength |
2 mg |
| Substance class |
Platinum-based antineoplastic agent |
| Trade name |
Eloxatin |
| Use in sports |
None |
| Water Retention |
None |
| Manufacturer |
Nanox |
